Holen Sie sich die Stockscreener-App
0.00
100.00%
-4.97
Bluebird Bio Inc Aktie (BLUE) Neueste Nachrichten
What analysts say about bluebird bio Inc. stockExplosive earnings growth - jammulinksnews.com
What drives bluebird bio Inc. stock priceMarket-beating performance - Autocar Professional
Is bluebird bio Inc. a good long term investmentHigh-octane financial growth - jammulinksnews.com
What makes bluebird bio Inc. stock price move sharplyMomentum Buy Alert - beatles.ru
Unexpected Trends Reshaping the Adeno Associated Virus (AVV) - openPR.com
Sickle Cell Disease Treatment Market is Expanding at a CAGR - openPR.com
BLUE LAWSUIT ALERT: Levi & Korsinsky Notifies bluebird bio, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
Bluebird bio’s Long-Term Study on CALD Treatment: A Potential Game Changer - TipRanks
bluebird bio Expands Leadership Team - citybiz
bluebird bio Bolsters Management Team with Appointments - Contract Pharma
Inside the Future of the Gene Therapy for SCID Market: Forecasts, - openPR.com
Carlyle and SK Capital Complete Acquisition of bluebird bio - orrick.com
Bluebird bio Requests to Dismiss Class Action Filed by Investors - TradingView
Bank of America Corp DE Sells 1,358,195 Shares of bluebird bio, Inc. (NASDAQ:BLUE) - Defense World
As Gene Therapy Endures ‘Cold Winter,’ FDA Leaders Promise Support - BioSpace
Adrenoleukodystrophy Treatment Market Overview | HSCT, Gene - openPR.com
Nuveen Asset Management LLC Decreases Stock Position in bluebird bio, Inc. (NASDAQ:BLUE) - Defense World
BNP Paribas Financial Markets Decreases Stake in bluebird bio, Inc. (NASDAQ:BLUE) - Defense World
bluebird bio, Inc. (BLUE) Nears Acquisition by Carlyle and SK Capital - MSN
Beta-Thalassemia (B-thal) Market Set to Witness - openPR.com
Sickle Cell Treatment Market 2025 | Advances, Drugs, Therapies & - openPR.com
bluebird bio acquired to scale gene therapy access By Investing.com - Investing.com Canada
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $47,000 Stake in bluebird bio, Inc. (NASDAQ:BLUE) - Defense World
Deutsche Bank AG Cuts Stake in bluebird bio, Inc. (NASDAQ:BLUE) - Defense World
Carlyle, SK Capital close deal for bluebird bio, injecting capital for commercial expansion - The Business Journals
Bluebird Bio (BLUE) Acquired by Carlyle and SK Capital Partners | BLUE Stock News - GuruFocus
bluebird bio Announces Completion of Acquisition by Carlyle and SK Capital | BLUE Stock News - GuruFocus
Carlyle, SK Capital Partners Close Bluebird Bio Acquisition - marketscreener.com
Bluebird Bio Announces Completion Of Acquisition By Carlyle And SK Capital - marketscreener.com
bluebird bio acquired to scale gene therapy access - Investing.com
bluebird bio Announces Completion of Acquisition by Carlyle and SK Capital - Business Wire
Carlyle, SK Capital Partners disclose expected closing date of bluebird bio deal - MSN
Carlyle and SK Capital to acquire bluebird bio By Investing.com - Investing.com South Africa
Northern Trust Corp Reduces Holdings in bluebird bio, Inc. (NASDAQ:BLUE) - Defense World
The Gene Therapy Valuation Reset: A Strategic Investor's Opportunity in Bluebird Bio's Acquisition - AInvest
Bluebird Bio (BLUE) Acquisition Nears Completion - GuruFocus
Carlyle, SK Capital, Beacon Set To Close Bluebird Bio Acquisition - Nasdaq
Carlyle and SK Capital Partners Announce Expiration of bluebird bio Tender Offer - marketscreener.com
Carlyle and SK Capital to acquire bluebird bio - Investing.com India
Carlyle-Led Group Closes Tender Offer for Bluebird Bio - marketscreener.com
Carlyle and SK Capital Partners Announce Expiration of bluebird bio Tender Offer | BLUE Stock News - GuruFocus
Carlyle's $5 Per Share Bluebird Bio Takeover Set for June 2 Close After Successful Tender - Stock Titan
Bluebird Bio's Acquisition Deal Offers Shareholders New Cash Option - Finimize
0.87%
0.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):